Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin. - ECP

Johannes Gutenberg Universität Mainz0 个研究点目标入组 58 人开始时间: 2009年2月19日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•There is a preoperative allergy testing.
•- There is a histology finding.
•- There is a CT scan of the sinuses, which confirmed the diagnosis of chronic rhinosinusitis.
•- Candidates in the location, type, extent and consequences of individual clinical trial is to be understood. - A lies in front of the candidates personally signed and dated consent form before any test-specific measure is implemented.
•- Women who are postmenopausal for more than two years, to attend the trial. Women of childbearing age can only participate in the trial if they are surgically sterile, or if they are willing to use reliable contraception during the trial and up to two months after the end of the trial.

•- Pregnancy and lactation.
•- Hypersensitivity to the investigational product or a chemically related substance or a component of the investigational product or placebo.
•- The existence of a unilateral rhinosinusitis, a tumor of the paranasal sinuses, a fungal sinusitis, sinusitis in cystic fibrosis or a part of a syndrome of immotile cilia.
•- Well-known liver or kidney disease, electrolyte disturbances or heart rhythm disturbances, especially QT interval prolongations.
•- Regular use of drugs, of which a known interaction is known with simultaneous administration of macrolides.
•- Participation in other clinical trials during or within 6 months prior to this trial.
•- Medical or psychological circumstances that may endanger the proper conduct of the trial.

发起方